PIPELINE OVERVIEW

Redefining topical therapies – providing  patients a new treatment experience 

Skin and eye diseases may negatively affect the appearance and quality of life, why patients are highly involved in the choice of therapy. Patients should expect and are looking for therapies that are not only safe and efficacious, but also convenient and easy to use in daily routines – in particular in the case of life-long chronic diseases.

Sometimes new topical therapies are difficult to develop for reasons of stability or solubility of the active ingredients or due to difficulties in delivering active ingredients into the target tissue in the skin or eyes. This often results in the termination of development of otherwise promising new therapies or in suboptimal formulations of the products that patients do not like to use in daily routines, e.g. because they are greasy (stain clothes and bedding) or causes stinging and burning. Empiric evidence shows that patients are less likely to use such inferior products as prescribed, which results in poor real-life efficacy and satisfaction. These dynamics cause patients to discontinue therapies, shift to more convenient, but less effective topicals or to shift to much more expensive systemic (oral or injectable) therapies.

PAD™ Technology enables new topical formulations of potent active ingredients into PAD™ creams or PAD™ eye drops,  designed to be pleasant for patients to use in daily routines, while optimizing delivery of the active ingredients into the target tissue thereby releasing the full potential. This enables formulation of new active ingredients into topical therapies and an opportunity to significantly upgrade existing leading drugs. PAD™ Technology enables a new standard in topical therapies for chronic inflammatory conditions by releasing the full potential of active ingredients in formulations designed for high tolerability and patient convenience.

Our current pipeline includes several PAD™ based drug candidates as well as a novel non-drug skincare line BioMee™ designed for dry, itchy and sensitive skin.

Our drug programs are addressing major chronic inflammatory diseases such as psoriasis, atopic dermatitis, uremic pruritus, dry skin and dry eyes:

Wynzora™ Cream

Read more

Active ingredient: Calcipotriene/betamethasone dipropionate
Indication: Plaque psoriasis

MC2-03 PAD™ Eye Drop

Read more

Active ingredient: Ciclosporin
Indication: Moderate to severe dry eye

MC2-11 PAD™ Cream

Read more

Active ingredient: Tacrolimus
Indication: Atopic Dermatitis

MC2-22 PAD™ Cream

Read more

Active ingredient: Crisaborole 
Indication: Mild to moderate atopic dermatitis

MC2-25 PAD™ Cream

Read more

Active ingredient: Undisclosed
Indication: Uremic pruritus and associated dry skin

© mc2 therapeutics 2020